Attention Deficit-Hyperactivity Disorder (ADHD)

Categories: Genetic diseases, Mental diseases, Neuronal diseases, Oral diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Attention Deficit-Hyperactivity Disorder

MalaCards integrated aliases for Attention Deficit-Hyperactivity Disorder:

Name: Attention Deficit-Hyperactivity Disorder 57 52 38
Attention Deficit Hyperactivity Disorder 39 11 42 75 28 5 41 14 63 16 71 33
Adhd 57 39 11 42 2 14
Attention Deficit Disorder 11 42 53 71
Attention Deficit-Hyperactivity Disorder, Susceptibility to 57 12 5
Attention Deficit Disorder with Hyperactivity 42 43 33
Hyperkinetic Disorder 11 42
Attention-Deficit/hyperactivity Disorder, Predominantly Inattentive Type 71
Attention Deficit Disorder of Childhood with Hyperactivity 42
Attention Deficit Disorder with Hyperactivity Syndrome 42
Disorder of Activity and Attention with Hyperkinesia 33
Adhd - [attention Deficit Hyperactivity Disorder] 33
Attention Deficit Syndrome with Hyperactivity 33
Attention-Deficit/hyperactivity Disorder 42
Attention-Deficit Hyperactivity Disorder 53
Disturbance of Activity and Attention 33
Disorder of Activity and Attention 33
Hyperactivity of Childhood 57
Hyperkinetic Disorders 33
Hyperkinetic Syndrome 42
Attention Deficit 42
Addh 42
Add 42



Autosomal dominant 57


External Ids:

Disease Ontology 11 DOID:1094
OMIM® 57 143465
MeSH 43 D001289
SNOMED-CT 68 229713001
ICD10 31 F90 F90.0 F90.9
MedGen 40 C1263846
SNOMED-CT via HPO 69 406506008 44548000 7461003
ICD11 33 821852937
UMLS 71 C0041671 C0339002 C1263846

Summaries for Attention Deficit-Hyperactivity Disorder

MedlinePlus Genetics: 42 Attention-deficit/hyperactivity disorder (ADHD) is a behavioral disorder that typically begins in childhood and is characterized by a short attention span (inattention), an inability to be calm and stay still (hyperactivity), and poor impulse control (impulsivity). Some people with ADHD have problems with only inattention or with hyperactivity and impulsivity, but most have problems related to all three features.In people with ADHD, the characteristic behaviors are frequent and severe enough to interfere with the activities of daily living such as school, work, and relationships with others. Because of an inability to stay focused on tasks, people with inattention may be easily distracted, forgetful, avoid tasks that require sustained attention, have difficulty organizing tasks, or frequently lose items.Hyperactivity is usually shown by frequent movement. Individuals with this feature often fidget or tap their foot when seated, leave their seat when it is inappropriate to do so (such as in the classroom), or talk a lot and interrupt others.Impulsivity can result in hasty actions without thought for the consequences. Individuals with poor impulse control may have difficulty waiting for their turn, deferring to others, or considering their actions before acting.More than two-thirds of all individuals with ADHD have additional conditions, including insomnia, mood or anxiety disorders, learning disorders, or substance use disorders. Affected individuals may also have autism spectrum disorder, which is characterized by impaired communication and social interaction, or Tourette syndrome, which is a disorder characterized by repetitive and involuntary movements or noises called tics.In most affected individuals, ADHD continues throughout life, but in about one-third of individuals, signs and symptoms of ADHD go away by adulthood.

MalaCards based summary: Attention Deficit-Hyperactivity Disorder, also known as attention deficit hyperactivity disorder, is related to oppositional defiant disorder and gilles de la tourette syndrome, and has symptoms including tremor, back pain and headache. An important gene associated with Attention Deficit-Hyperactivity Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Neurotransmitter clearance and Methylphenidate Pathway, Pharmacodynamics. The drugs Sertraline and Lithium carbonate have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and cingulate cortex, and related phenotypes are attention deficit hyperactivity disorder and hyperactivity

PubMed Health : 63 Attention deficit hyperactivity disorder: Attention deficit hyperactivity disorder, ADHD, is a mental disorder in which children are especially inattentive, impulsive or hyperactive. “Inattentive” refers to children who have difficulties focusing and are easily distracted. Overly “impulsive” children act in a way that is extremely rash, inconsiderate, careless or impatient for their age. “Hyperactive” describes children who are restless or constantly fidgeting – for instance, they may not be able to sit still during school lessons, and get up and walk around the classroom a lot instead. Severe ADHD can cause major problems in the life and everyday routine of both the child and their parents and brothers and sisters: Because children with ADHD behave differently than expected, they often cause trouble. They need a lot of attention. They find it more difficult to learn because of their short attention span. ADHD may also be accompanied by other kinds of mental disorders. The number of children being diagnosed with ADHD has increased in recent years. Some people are wary of this development and doubt that ADHD is really that common. They are worried that a lot of children who are diagnosed with ADHD are simply a little overactive, but otherwise healthy. A wrong diagnosis may lead to unnecessary treatment. Being wrongly labelled as mentally ill may also affect a child’s self-esteem. But there are also children and teenagers who actually have ADHD but are not diagnosed with it. This can also have a negative effect, because they may not get treatment that could help them. So it is very important to take the time to look into things so ADHD can be ruled out or diagnosed.

MedlinePlus: 41 Is it hard for your child to sit still? Does your child act without thinking first? Does your child start but not finish things? If so, your child may have attention deficit hyperactivity disorder (ADHD). Nearly everyone shows some of these behaviors at times, but ADHD lasts more than 6 months and causes problems in school, at home and in social situations. ADHD is more common in boys than girls. It affects 3 to 5% of all American children. The main features of ADHD are: Inattention Hyperactivity Impulsivity No one knows exactly what causes ADHD. It sometimes runs in families, so genetics may be a factor. There may also be environmental factors. A complete evaluation by a trained professional is the only way to know for sure if your child has ADHD. Treatment may include medicine to control symptoms, therapy, or both. Structure at home and at school is important. Parent training may also help. NIH: National Institute of Mental Health

NINDS: 52 Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral). Some of the warning signs of ADHD include failure to listen to instructions, inability to organize oneself and school work, fidgeting with hands and feet, talking too much, leaving projects, chores and homework unfinished, and having trouble paying attention to and responding to details. There are several types of ADHD: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. ADHD is usually diagnosed in childhood, although the condition can continue into the adult years.

OMIM®: 57 Attention deficit-hyperactivity disorder (ADHD) is the most common childhood-onset behavioral disorder, affecting approximately 5 to 10% of children and adolescents (Wolraich et al., 1996). In this condition, persistent inattention and/or hyperactive-impulsive behavior results in impaired social and/or academic functioning. Boys are affected about 8 times more frequently than girls (Zametkin et al., 1990). (143465) (Updated 08-Dec-2022)

CDC: 2 ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often lasts into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors (may act without thinking about what the result will be), or be overly active.

Disease Ontology: 11 A specific developmental disorder that is characterized by co-existence of attentional problems and hyperactivity, with each behavior occurring infrequently alone and symptoms starting before seven years of age.

Wikipedia: 75 Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterised by... more...

Related Diseases for Attention Deficit-Hyperactivity Disorder

Diseases in the Attention Deficit-Hyperactivity Disorder family:

Attention Deficit-Hyperactivity Disorder 1 Attention Deficit-Hyperactivity Disorder 2
Attention Deficit-Hyperactivity Disorder 3 Attention Deficit-Hyperactivity Disorder 4
Attention Deficit-Hyperactivity Disorder 8

Diseases related to Attention Deficit-Hyperactivity Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1616)
# Related Disease Score Top Affiliating Genes
1 oppositional defiant disorder 33.5 SLC6A3 DRD5 DRD4 COMT
2 gilles de la tourette syndrome 33.4 SLC6A3 DRD5 DRD4 COMT
3 learning disability 33.3 MECP2 DRD4 COMT
4 conduct disorder 33.1 SLC6A3 DRD5 DRD4 COMT
5 impulse control disorder 33.0 SLC6A3 DRD5 DRD4 COMT
6 anxiety 32.9 SLC6A3 MECP2 DRD4 COMT
7 personality disorder 32.9 SLC6A3 DRD4 COMT
8 tic disorder 32.8 SLC6A3 DRD5 DRD4 COMT
9 chromosome 22q11.2 deletion syndrome, distal 32.8 SLC6A3 MECP2 COMT
10 substance abuse 32.8 SLC6A3 DRD4 COMT
11 developmental delay, behavioral abnormalities, and neuropsychiatric disorders 32.7 ADGRL1-AS1 ADGRL1
12 major depressive disorder 32.7 SLC6A3 DRD5 DRD4 COMT
13 alcohol use disorder 32.6 SLC6A3 DRD4 COMT
14 psychotic disorder 32.4 SLC6A3 MECP2 DRD5 DRD4 COMT
15 antisocial personality disorder 32.4 SLC6A3 DRD4 COMT
16 schizophrenia 32.3 VPS13B SLC6A3 MECP2 MAP1B DRD5 DRD4
17 disease of mental health 32.3 SLC6A3 MECP2 DRD4 COMT
18 obsessive-compulsive disorder 32.3 SLC6A3 DRD4 COMT
19 bulimia nervosa 32.3 SLC6A3 DRD4 COMT
20 tobacco addiction 32.2 SLC6A3 DRD4 COMT
21 substance dependence 32.2 SLC6A3 DRD5 DRD4 COMT
22 dysthymic disorder 32.2 SLC6A3 DRD4 COMT
23 restless legs syndrome 32.1 SLC6A3 DRD4 COMT
24 drug dependence 32.1 SLC6A3 DRD4 COMT
25 speech and communication disorders 32.1 SLC6A3 MECP2 COMT
26 bruxism 32.0 MECP2 DRD5 COMT
27 specific learning disability 32.0 ADGRL1-AS1 ADGRL1
28 migraine with or without aura 1 31.9 SLC6A3 DRD5 DRD4 COMT
29 opiate dependence 31.8 SLC6A3 DRD4 COMT
30 separation anxiety disorder 31.8 DRD4 COMT
31 pathological gambling 31.6 SLC6A3 DRD5 DRD4 COMT
32 panic disorder 31.6 SLC6A3 DRD4 COMT
33 cyclothymic disorder 31.6 DRD4 COMT
34 avoidant personality disorder 31.4 SLC6A3 DRD4
35 kleptomania 31.4 SLC6A3 COMT
36 cannabis abuse 31.3 DRD4 COMT
37 heroin dependence 31.1 SLC6A3 DRD4 COMT
38 hypotonia 31.1 VPS13B MECP2 MAP1B DOCK3
39 drug psychosis 31.0 SLC6A3 COMT
40 specific developmental disorder 30.8 SLC6A3 MECP2 DRD5 DRD4 COMT
41 speech disorder 30.6 SLC6A3 SCAPER MECP2
42 delusional disorder 30.5 SLC6A3 DRD4 COMT
43 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 11.9
44 catifa syndrome 11.8
45 attention deficit-hyperactivity disorder 1 11.8
46 attention deficit-hyperactivity disorder 3 11.8
47 attention deficit-hyperactivity disorder 2 11.7
48 attention deficit-hyperactivity disorder 4 11.7
49 attention deficit-hyperactivity disorder 8 11.6
50 bipolar disorder 11.6

Graphical network of the top 20 diseases related to Attention Deficit-Hyperactivity Disorder:

Diseases related to Attention Deficit-Hyperactivity Disorder

Symptoms & Phenotypes for Attention Deficit-Hyperactivity Disorder

Human phenotypes related to Attention Deficit-Hyperactivity Disorder:

# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 attention deficit hyperactivity disorder 30 HP:0007018
2 hyperactivity 30 HP:0000752

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)

male:female ratio 8:1

Clinical features from OMIM®:

143465 (Updated 08-Dec-2022)

UMLS symptoms related to Attention Deficit-Hyperactivity Disorder:

tremor; back pain; headache; syncope; pain; chronic pain; sciatica; seizures; vertigo/dizziness; sleeplessness

MGI Mouse Phenotypes related to Attention Deficit-Hyperactivity Disorder:

# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.7 ADGRL1 CDK20 COMT DOCK3 DRD4 DRD5
2 behavior/neurological MP:0005386 9.4 ADGRL1 COMT DOCK3 DRD4 DRD5 GNB5

Drugs & Therapeutics for Attention Deficit-Hyperactivity Disorder

PubMed Health treatment related to Attention Deficit-Hyperactivity Disorder: 63

Before any treatment is started, the doctor will talk about what ADHD is and how everyone can best cope with it. As well as the parents and their child, teachers and preschool teachers may also be there too. It may then turn out that there is no urgent need for treatment. When deciding whether or not treatment is necessary, it is important to consider how much of a problem the behavior is for the child and their parents, and whether things like their performance at school are suffering as a result. If a child only has a mild form of ADHD that does not affect his or her life too much, it might be enough to complete a parent training and education program on dealing with ADHD. These programs can be taken as a class with an instructor or done on your own using written material. If a child has moderate or severe ADHD that is causing problems at school and in their social environment, it may be helpful to try interventions at school or have family or behavioral therapy . The type of help that will be most effective will depend on the child’s age, whether they tend to be more inattentive or more hyperactive, and what areas of their life the ADHD has the greatest impact on. Medication can relieve ADHD symptoms. It is mainly considered for the treatment of more severe ADHD when psychological and educational approaches are not effective enough. Medicine containing the drug methylphenidate is the most commonly used medication. If methylphenidate does not work or cannot be used for other reasons, the drugs atomoxetine , dexamfetamine or lisdexamfetamine may be used instead. Treatment at a psychosomatic or psychiatric hospital for children and teenagers may be a good idea for children who are extremely hyperactive and impulsive and have great difficulty coping in daily life, or can no longer cope at all. Hospital treatment may also be needed if the child has other severe mental disorders too.

Drugs for Attention Deficit-Hyperactivity Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Sertraline Approved Phase 4 79617-96-2 68617
Lithium carbonate Approved Phase 4 554-13-2
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
Topiramate Approved Phase 4 97240-79-4 5284627
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
Norepinephrine Approved Phase 4 51-41-2 439260
Galantamine Approved Phase 4 357-70-0, 1953-04-4 9651
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
Cyproheptadine Approved Phase 4 129-03-3 2913
Metamfetamine Approved, Illicit, Withdrawn Phase 4 537-46-2 10836
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
Histamine Approved, Investigational Phase 4 51-45-6 774
Cariprazine Approved, Investigational Phase 4 839712-12-8 11154555
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
Viloxazine Approved, Investigational, Withdrawn Phase 4 46817-91-8 5666
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
Dextroamphetamine Approved, Illicit, Investigational Phase 4 51-64-9, 300-62-9 5826 3007
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
29 Sulfalene Phase 4
30 Anti-Infective Agents Phase 4
31 Antiprotozoal Agents Phase 4
32 Antiparasitic Agents Phase 4
33 Antimalarials Phase 4
34 Antiparkinson Agents Phase 4
35 Dopamine agonists Phase 4
36 Analgesics Phase 4
37 Sympatholytics Phase 4
38 Antidepressive Agents Phase 4
39 Serotonin Uptake Inhibitors Phase 4
40 Serotonin Receptor Agonists Phase 4
41 Serotonin 5-HT1 Receptor Agonists Phase 4
42 Nootropic Agents Phase 4
43 Cholinesterase Inhibitors Phase 4
44 Excitatory Amino Acid Antagonists Phase 4
45 Vasoconstrictor Agents Phase 4
46 Antiemetics Phase 4
47 Analgesics, Opioid Phase 4
48 Gastrointestinal Agents Phase 4
49 Anti-Allergic Agents Phase 4
50 Histamine H1 Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 1439)
# Name Status NCT ID Phase Drugs
1 Rhodiola Rosea in Adults With Attention Deficit/Hyperactivity Disorder Unknown status NCT02737020 Phase 4 Rhodiola;Placebo
2 A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT02677519 Phase 4 Aptensio XR
3 International Study to Predict Optimised Treatment Response to Short or Long Acting Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder. Unknown status NCT00863499 Phase 4 Short Acting Methylphenidate;Long Acting Methylphenidate
4 Comprehensive Pathophysiological Study Based on the Core Neurocognitive Deficits and Development of Biological Markers of Treatment Response in Attention Deficit Hyperactivity Disorder Unknown status NCT02623114 Phase 4 methylphenidate;atomoxetine
5 Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
6 Effects of 800mg of Rhodiola Rosea in Attention in Adults With Attention-Deficit/Hyperactivity Disorder Unknown status NCT02737033 Phase 4 Rhodiola;Placebo
7 A Cognitive Behavioral Therapy Group Intervention for Adolescents With Attention-Deficit / Hyperactivity Disorder Unknown status NCT02566824 Phase 4 Methylphenidate or amphetamine product
8 A Study to Identify the Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in Attention Deficit Hyperactivity Disorder Unknown status NCT02074228 Phase 4 Methylphenidate (Concerta)
9 Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT00152750 Phase 4 APO-clonidine
10 Comparing Treatment With Melatonin to Treatment With Stimulants (Methylphenidate) in Children With Attention Deficit Hyperactivity Disorder and Sleep Difficulties Unknown status NCT01393574 Phase 4 Melatonin;Methylphenidate
11 Functional Brain Markers and Predictors of Treatment Response Associated With Norepinephrine System Genes in ADHD Unknown status NCT00862108 Phase 4 Methylphenidate
12 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Unknown status NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
13 A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
14 The Effect of a Once Daily Evening Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents Unknown status NCT00252278 Phase 4 atomoxetine
15 Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder Unknown status NCT02477280 Phase 4 Methylphenidate;Placebo
16 Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children Unknown status NCT02545634 Phase 4
17 Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment Unknown status NCT01339286 Phase 4 atomoxetine
18 Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD Unknown status NCT00318981 Phase 4 Concerta
19 Methylphenidate Treatment of Children and Adolescents Diagnosed With ADHD and Its Influence on Comorbid Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
20 Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
21 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
22 A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder. Completed NCT00191906 Phase 4 Atomoxetine Hydrochloride;placebo
23 Early Interventions in Children With Attention Deficit/Hyperactivity Disorder: Randomized Controlled Trial Comparing Methylphenidate Parental Training in Treating Preschool Children With Attention Deficit / Hyperactivity Disorder Completed NCT02807870 Phase 4 Methylphenidate;Placebo pill
24 Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder Completed NCT01831622 Phase 4 Ritalin;Placebo
25 The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder Completed NCT00773916 Phase 4 Methylphenidate
26 Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment Completed NCT00716274 Phase 4 Atomoxetine;Placebo
27 A Phase IV, Real World, Open-label, Multi-centre Study on the Use of FOQUEST® (Methylphenidate Hydrochloride Controlled-release Capsules) for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Pediatric and Adult Patients Completed NCT04152629 Phase 4 Methylphenidate Hydrochloride;Lisdexamfetamine Dimesylate
28 A Multi-center Randomized Parallel Group Study Evaluating Treatment Outcomes of Concerta (Extended Release Methylphenidate) and Strattera (Atomoxetine) in Children With Attention-deficit/Hyperactivity Disorder Completed NCT00866996 Phase 4 Methylphenidate extended-release; Atomoxetine
29 Genetic Polymorphism of Drug Transporters in OROS-Methylphenidate Treatment in Children and Adolescents With Attention Deficit Hyperactivity Disorder(ADHD) Completed NCT00842127 Phase 4 OROS-methylphenidate (Concerta)
30 Feasibility and Utility of Autonomic Correlates of Impulsivity in Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD): Extending Translational Research Skills Completed NCT00856063 Phase 4 atomoxetine (or placebo)
31 A Multicenter Open Trial to Evaluate the Effectiveness and Quality of Life in Adults With Attention Deficit /Hyperactivity Disorder (ADHD) Treated With Long Acting Methylphenidate (CONCERTA) Completed NCT00783835 Phase 4 Long-Acting Methylphenidate
32 Functional Neuroimaging of Acute Concerta Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD): Differences Across Development Completed NCT00778310 Phase 4 methylphenidate-OROS;Placebo
33 Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder Completed NCT02096952 Phase 4 Methylphenidate extended-release liquid formulation
34 A Randomized, Double Blind Comparison of the Effects of Atomoxetine Versus Placebo on Neuropsychological Outcomes Across the Day in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) by Use of a Computer Based Continuous Performance Test (cb CPT) Completed NCT00546910 Phase 4 Atomoxetine;Placebo
35 An Open-Label, Multicenter, Pilot Study of the Safety and Efficacy of Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00485875 Phase 4 Atomoxetine Hydrochloride
36 Evaluation of Academic Performance in Asian Children Aged 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine Hydrochloride Completed NCT00471354 Phase 4 Atomoxetine
37 A Randomized, Double-Blind Comparison of the Time Course of Response to Two Extended-Release Oral Delivery Systems for Methylphenidate in Pediatric Patients With Attention Deficit Hyperactivity Disorder in an Analog Classroom Setting: The CoMACS Study Completed NCT00381758 Phase 4 Methylphenidate Extended Release Capsules
38 Effect of OROS-Methylphenidate (Concerta) on Different Domains of Attention and Working Memory in Children With Attention-Deficit/Hyperactivity Disorder Completed NCT00530257 Phase 4 Placebo;OROS-methylphenidate
39 An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01933880 Phase 4 Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)
40 Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study Completed NCT02255565 Phase 4 Very Low Dose Quillivant XR;Low Dose Quillivant XR;Moderate Dose Quillivant XR
41 A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD) Completed NCT02683265 Phase 4 Aptensio XR;Placebo
42 Treatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too) Completed NCT02675400 Phase 4 Vyvanse;Methylphenidate
43 A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning Compared With Fast Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00760747 Phase 4 Atomoxetine
44 An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00753012 Phase 4 Lisdexamfetamine
45 The Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS-Methylphenidate Completed NCT00518232 Phase 4 OROS-methylphenidate
46 A Randomized, Double-Blind, Parallel-Group, Analog Classroom Study, Evaluating ADDERALL XR Versus STRATTERA, Dosed Once Daily, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT00506727 Phase 4 Mixed amphetamine salts (ADDERALL XR);Atomoxetine hydrochloride
47 A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder Completed NCT00406354 Phase 4 Atomoxetine;Placebo
48 An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder. Completed NCT01873729 Phase 4 Naltrexone
49 A Randomized, Multi-center, Double-blind, Placebo-controlled, Cross-over Study Evaluating the Safety and Efficacy of Dex-Methylphenidate Extended Release 30 mg vs. 20 mg as Measured by SKAMP-Combined Scores in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting. Completed NCT00776009 Phase 4 Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR);Placebo
50 Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD): an Functional Magnetic Resonance Imaging(fMRI) Study of Brain Activation Pre and Post Treatment Completed NCT01709695 Phase 4 Guanfacine Hydrochloride XR;Placebo

Search NIH Clinical Center for Attention Deficit-Hyperactivity Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Amphetamine aspartate
Amphetamine Sulfate
atomoxetine hydrochloride
Bupropion hydrobromide
Bupropion Hydrochloride
Clonidine Hydrochloride
Desipramine Hydrochloride
dexmethylphenidate hydrochloride
Dextroamphetamine saccharate
Dextroamphetamine Sulfate
Imipramine Hydrochloride
Imipramine pamoate
Methylphenidate Hydrochloride
Nortriptyline Hydrochloride
selegiline hydrochloride
Venlafaxine hydrochloride

Cochrane evidence based reviews: attention deficit disorder with hyperactivity

Genetic Tests for Attention Deficit-Hyperactivity Disorder

Genetic tests related to Attention Deficit-Hyperactivity Disorder:

# Genetic test Affiliating Genes
1 Attention Deficit Hyperactivity Disorder 28 DRD4 DRD5

Anatomical Context for Attention Deficit-Hyperactivity Disorder

Organs/tissues related to Attention Deficit-Hyperactivity Disorder:

MalaCards : Brain, Prefrontal Cortex, Cingulate Cortex, Cortex, Amygdala, Eye, Whole Blood

Publications for Attention Deficit-Hyperactivity Disorder

Articles related to Attention Deficit-Hyperactivity Disorder:

(show top 50) (show all 40416)
# Title Authors PMID Year
Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5. 62 57 5
14699430 2004
Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD. 53 62 57
16197923 2006
Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit/hyperactivity disorder. 53 62 57
16172611 2006
Sequence variation in the 3'-untranslated region of the dopamine transporter gene and attention-deficit hyperactivity disorder (ADHD). 53 62 57
16082693 2005
Temperament and character profiles and the dopamine D4 receptor gene in ADHD. 53 62 57
15863792 2005
Dopamine receptor D4 (DRD4) gene in Han Chinese children with attention-deficit/hyperactivity disorder (ADHD): increased prevalence of the 2-repeat allele. 53 62 57
15578612 2005
DAT1, DRD4, and DRD5 polymorphisms are not associated with ADHD in Dutch families. 53 62 57
15389755 2005
Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. 53 62 5
14732906 2004
Association of the dopamine D4 receptor gene 7-repeat allele with neuropsychological test performance of children with ADHD. 53 62 57
14702261 2004
Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? 53 62 57
12815749 2003
Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD). 53 62 5
11032387 2000
Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. 53 62 57
10889551 2000
Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. 53 62 5
10208453 1999
Association of attention-deficit disorder and the dopamine transporter gene. 53 62 57
7717410 1995
Human CRY1 variants associate with attention deficit/hyperactivity disorder. 62 5
32538895 2020
Mutations in SCAPER cause autosomal recessive retinitis pigmentosa with intellectual disability. 62 5
28794130 2017
Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. 62 57
21835979 2011
GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice. 62 57
21499268 2011
Forebrain overexpression of CK1delta leads to down-regulation of dopamine receptors and altered locomotor activity reminiscent of ADHD. 62 57
20145109 2010
Parent-of-origin effect and risk for attention-deficit/hyperactivity disorder: balancing the evidence against bias and chance findings. 62 57
16960815 2006
Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. 62 57
16236810 2006
A genome-wide scan for attention-deficit/hyperactivity disorder in 155 German sib-pairs. 62 57
16222334 2006
A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. 62 57
16389200 2006
Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder. 62 57
16380908 2005
The SNAP25 gene as a susceptibility gene contributing to attention-deficit hyperactivity disorder. 62 57
16088329 2005
No support for association between the dopamine transporter (DAT1) gene and ADHD. 62 57
16082688 2005
Catechol O-methyltransferase gene variant and birth weight predict early-onset antisocial behavior in children with attention-deficit/hyperactivity disorder. 62 57
16275815 2005
Attention-deficit/hyperactivity disorder in a population isolate: linkage to loci at 4q13.2, 5q33.3, 11q22, and 17p11. 62 57
15497111 2004
Attention deficit hyperactivity disorder: fine mapping supports linkage to 5p13, 6q12, 16p13, and 17p11. 62 57
15297934 2004
Genome-wide scan of reading ability in affected sibling pairs with attention-deficit/hyperactivity disorder: unique and shared genetic effects. 62 57
14625563 2004
Co-occurrence of ADHD and low IQ has genetic origins. 62 57
14681911 2004
Disruption of a novel member of a sodium/hydrogen exchanger family and DOCK3 is associated with an attention deficit hyperactivity disorder-like phenotype. 62 57
14569117 2003
Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors. 62 57
12915833 2003
A genomewide scan for attention-deficit/hyperactivity disorder in an extended sample: suggestive linkage on 17p11. 62 57
12687500 2003
A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. 62 57
12679898 2003
The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. 62 57
12556913 2003
Genetic linkage of attention-deficit/hyperactivity disorder on chromosome 16p13, in a region implicated in autism. 62 57
12187510 2002
A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. 62 57
11923911 2002
Attention-deficit/hyperactivity disorder (ADHD): feasibility of linkage analysis in a genetic isolate using extended and multigenerational pedigrees. 62 57
12081716 2002
Quantitative trait locus for reading disability on chromosome 6p is pleiotropic for attention-deficit/hyperactivity disorder. 62 57
11920845 2002
The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). 62 57
12192625 2002
Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. 62 57
12192616 2002
Problems in the management of attention-deficit-hyperactivity disorder. 62 57
9878644 1999
Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. 62 57
9837830 1998
Genetic influences in childhood-onset psychiatric disorders: autism and attention-deficit/hyperactivity disorder. 62 57
9199546 1997
Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. 62 57
8714320 1996
Cerebral glucose metabolism in adults with hyperactivity of childhood onset. 62 57
2233902 1990
Family-genetic and psychosocial risk factors in DSM-III attention deficit disorder. 62 57
2387786 1990
Parent training for the treatment of irritability in children and adolescents: a multisite randomized controlled, 3-parallel-group, evaluator-blinded, superiority trial. 62 41
36414963 2022
Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trial. 62 41
36443712 2022

Variations for Attention Deficit-Hyperactivity Disorder

ClinVar genetic disease variations for Attention Deficit-Hyperactivity Disorder:

5 (show all 45)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CRY1 NM_004075.5(CRY1):c.1657+3A>C SNV Association
427574 rs184039278 GRCh37: 12:107386740-107386740
GRCh38: 12:106992962-106992962
2 CRY1 NM_004075.5(CRY1):c.825+1G>A SNV Association
1344736 GRCh37: 12:107393719-107393719
GRCh38: 12:106999941-106999941
3 ADGRL1-AS1, ADGRL1 NM_014921.5(ADGRL1):c.819G>A (p.Trp273Ter) SNV Pathogenic
1700602 GRCh37: 19:14273794-14273794
GRCh38: 19:14162982-14162982
4 ADGRL1-AS1, ADGRL1 NM_014921.5(ADGRL1):c.2998T>C (p.Trp1000Arg) SNV Pathogenic
1700599 GRCh37: 19:14267505-14267505
GRCh38: 19:14156693-14156693
5 ADGRL1-AS1, ADGRL1 NM_014921.5(ADGRL1):c.3476C>T (p.Ser1159Phe) SNV Pathogenic
1700604 GRCh37: 19:14263373-14263373
GRCh38: 19:14152561-14152561
6 overlap with 6 genes GRCh37/hg19 17p12(chr17:14215739-15422582) CN LOSS Pathogenic
523259 GRCh37: 17:14215739-15422582
7 ADGRL1-AS1, ADGRL1 NM_014921.5(ADGRL1):c.2049dup (p.Glu684fs) DUP Pathogenic
1700605 GRCh37: 19:14270001-14270002
GRCh38: 19:14159189-14159190
8 MECP2 NM_001110792.2(MECP2):c.1200_1220delinsCTGAGCCCCAGGACTTGAGCA (p.Pro401_Ser407delinsTer) INDEL Pathogenic
189665 rs786205019 GRCh37: X:153296095-153296115
GRCh38: X:154030644-154030664
9 C12orf57 NM_138425.4(C12orf57):c.53-2A>G SNV Pathogenic
242885 rs1114167293 GRCh37: 12:7053637-7053637
GRCh38: 12:6944474-6944474
10 VPS13B NM_152564.5(VPS13B):c.1219C>T (p.Gln407Ter) SNV Pathogenic
56645 rs386834070 GRCh37: 8:100146872-100146872
GRCh38: 8:99134644-99134644
11 MAP1B NM_005909.5(MAP1B):c.5368C>T (p.Arg1790Ter) SNV Pathogenic
638688 rs1580027036 GRCh37: 5:71494550-71494550
GRCh38: 5:72198723-72198723
12 overlap with 47 genes GRCh37/hg19 22q11.21(chr22:18894835-21505417) CN LOSS Pathogenic
523274 GRCh37: 22:18894835-21505417
13 CDK20 NM_001039803.3(CDK20):c.564G>A (p.Trp188Ter) SNV Pathogenic
375376 rs1057519438 GRCh37: 9:90584834-90584834
GRCh38: 9:87969919-87969919
14 HIVEP1 NM_002114.4(HIVEP1):c.4089G>C (p.Met1363Ile) SNV Pathogenic
375377 rs776300630 GRCh37: 6:12124117-12124117
GRCh38: 6:12123884-12123884
15 SCAPER NM_020843.3(SCAPER):c.2973_2976del (p.Ile991Metfs) MICROSAT Pathogenic
417685 rs1555447569 GRCh37: 15:76763655-76763658
GRCh38: 15:76471314-76471317
16 overlap with 65 genes GRCh37/hg19 3q23-25.32(chr3:142729607-157921084)x3 CN GAIN Pathogenic
1330165 GRCh37: 3:142729607-157921084
17 TBR1 NM_006593.4(TBR1):c.553C>T (p.Gln185Ter) SNV Likely Pathogenic
932939 rs1553510182 GRCh37: 2:162273474-162273474
GRCh38: 2:161416963-161416963
18 TBR1 NM_006593.4(TBR1):c.933_934insCAAAGGA (p.Thr312fs) INSERT Likely Pathogenic
932940 rs1684167000 GRCh37: 2:162274797-162274798
GRCh38: 2:161418286-161418287
19 TMEM47 NM_031442.4(TMEM47):c.35G>C (p.Arg12Pro) SNV Likely Pathogenic
242889 rs1114167296 GRCh37: X:34675112-34675112
GRCh38: X:34656995-34656995
20 MAGED2 NM_177433.3(MAGED2):c.1003del (p.Gln335fs) DEL Likely Pathogenic
242888 rs1114167295 GRCh37: X:54838602-54838602
GRCh38: X:54812169-54812169
21 KIF5B NM_004521.3(KIF5B):c.2252A>G (p.His751Arg) SNV Likely Pathogenic
242891 rs1114167297 GRCh37: 10:32308840-32308840
GRCh38: 10:32019912-32019912
22 DRD4 NG_021241.1:g.2522_3761= INSERT Risk Factor
16769 GRCh37: 11:634826-636065
GRCh38: 11:634826-636065
23 DRD5 DRD5, (CA)n MARKER VAR Risk Factor
16766 rs1553860005 GRCh37:
24 C12orf4 NM_020374.4(C12orf4):c.639_640insACAA (p.Gln214fs) INSERT Likely Pathogenic
183276 rs730882197 GRCh37: 12:4634508-4634509
GRCh38: 12:4525342-4525343
25 CHAF1B NM_005441.3(CHAF1B):c.496A>G (p.Ile166Val) SNV Likely Pathogenic
183350 rs140630794 GRCh37: 21:37769727-37769727
GRCh38: 21:36397429-36397429
26 TCF20 NM_001378418.1(TCF20):c.5725C>T (p.His1909Tyr) SNV Likely Pathogenic
590780 rs1569110700 GRCh37: 22:42575639-42575639
GRCh38: 22:42179633-42179633
27 GNB5 NM_016194.4(GNB5):c.368C>T (p.Ser123Leu) SNV Likely Pathogenic
254029 rs761399728 GRCh37: 15:52446144-52446144
GRCh38: 15:52153947-52153947
28 ADGRL1 NM_014921.5(ADGRL1):c.26G>A (p.Trp9Ter) SNV Likely Pathogenic
1700603 GRCh37: 19:14294389-14294389
GRCh38: 19:14183577-14183577
29 MAOA NM_000240.4(MAOA):c.331G>A (p.Ala111Thr) SNV Uncertain Significance
977422 rs755919316 GRCh37: X:43571143-43571143
GRCh38: X:43711896-43711896
30 TLN1 NM_006289.4(TLN1):c.2176dup (p.Thr726fs) DUP Uncertain Significance
1705026 GRCh37: 9:35717424-35717425
GRCh38: 9:35717427-35717428
31 CACNA1A NM_001127222.2(CACNA1A):c.7266_7271del (p.Ser2423_Gly2424del) DEL Uncertain Significance
598990 rs775428832 GRCh37: 19:13318377-13318382
GRCh38: 19:13207563-13207568
32 CLCN2 NM_004366.6(CLCN2):c.775G>A (p.Val259Ile) SNV Uncertain Significance
598991 rs757549500 GRCh37: 3:184075273-184075273
GRCh38: 3:184357485-184357485
33 ZBTB10 NM_001105539.3(ZBTB10):c.466C>T (p.Arg156Ter) SNV Uncertain Significance
1684521 GRCh37: 8:81399511-81399511
GRCh38: 8:80487276-80487276
34 overlap with 13 genes GRCh37/hg19 3q29(chr3:195457650-196263123) CN LOSS Uncertain Significance
523280 GRCh37: 3:195457650-196263123
35 RFX3 NM_001282116.2(RFX3):c.475-3C>G SNV Uncertain Significance
1065847 GRCh37: 9:3301623-3301623
GRCh38: 9:3301623-3301623
36 MINK1 NM_153827.5(MINK1):c.3206T>G (p.Leu1069Arg) SNV Uncertain Significance
1684526 GRCh37: 17:4798765-4798765
GRCh38: 17:4895470-4895470
37 overlap with 4 genes DEL Uncertain Significance
559400 GRCh37: 10:19906553-20105884
GRCh38: 10:19617624-19816955
38 TBC1D9 NM_015130.3(TBC1D9):c.3535C>T (p.His1179Tyr) SNV Uncertain Significance
690308 rs1578810332 GRCh37: 4:141543615-141543615
GRCh38: 4:140622461-140622461
39 DAGLA NM_006133.3(DAGLA):c.3049G>C (p.Asp1017His) SNV Uncertain Significance
690309 rs199764983 GRCh37: 11:61511881-61511881
GRCh38: 11:61744409-61744409
40 QARS1 NM_005051.3(QARS1):c.1412G>A (p.Cys471Tyr) SNV Uncertain Significance
690310 rs1575400316 GRCh37: 3:49137057-49137057
GRCh38: 3:49099624-49099624
41 CSMD2 NM_001281956.2(CSMD2):c.2671A>G (p.Ile891Val) SNV Uncertain Significance
690311 rs756789191 GRCh37: 1:34190974-34190974
GRCh38: 1:33725373-33725373
42 WDR83 NM_001099737.3(WDR83):c.379G>C (p.Gly127Arg) SNV Uncertain Significance
690312 rs749052560 GRCh37: 19:12781425-12781425
GRCh38: 19:12670611-12670611
43 overlap with 14 genes GRCh37/hg19 22q11.21(chr22:20728956-21465662)x3 CN GAIN Uncertain Significance
692091 GRCh37: 22:20728956-21465662
44 MECP2 NM_001110792.2(MECP2):c.1351G>A (p.Ala451Thr) SNV Likely Benign
143458 rs61753973 GRCh37: X:153295964-153295964
GRCh38: X:154030513-154030513
45 DEAF1 NM_021008.4(DEAF1):c.667G>A (p.Gly223Ser) SNV Likely Benign
373980 rs1057518811 GRCh37: 11:686995-686995
GRCh38: 11:686995-686995

Copy number variations for Attention Deficit-Hyperactivity Disorder from CNVD:

6 (show top 50) (show all 84)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 34465 1 56053497 56064495 Deletion USP24 Attention deficit hyperactivity disorder
2 34466 1 56053497 56064495 Deletion Attention deficit hyperactivity disorder
3 36125 1 72317292 72328395 Duplication NEGR1 Attention deficit hyperactivity disorder
4 49516 11 107520009 107885084 Duplication C11orf65 Attention deficit hyperactivity disorder
5 49517 11 107520009 107885084 Duplication EXPH5 Attention deficit hyperactivity disorder
6 49518 11 107520009 107885084 Duplication POGLUT3 Attention deficit hyperactivity disorder
7 60337 11 85300000 92300000 Deletion GRM5 Attention deficit hyperactivity disorder
8 60583 11 88269449 88351661 Deletion GRM5 Attention deficit hyperactivity disorder
9 60585 11 88269449 88351661 Het ACAT1 Attention deficit hyperactivity disorder
10 60586 11 88269449 88351661 Het ATM Attention deficit hyperactivity disorder
11 60587 11 88269449 88351661 Het GRM5 Attention deficit hyperactivity disorder
12 60588 11 88269449 88351661 Het NPAT Attention deficit hyperactivity disorder
13 63163 12 115300000 116700000 Duplicated NOS1 Attention deficit hyperactivity disorder
14 69603 12 55902280 55923860 Deletion NDUFA4L2 Attention deficit hyperactivity disorder
15 69604 12 55902280 55923860 Deletion NXPH4 Attention deficit hyperactivity disorder
16 69605 12 55902280 55923860 Deletion SHMT2 Attention deficit hyperactivity disorder
17 69606 12 55902280 55923860 Deletion STAC3 Attention deficit hyperactivity disorder
18 75846 13 24844208 25493420 Duplication or deletion ATP8A2 Attention deficit hyperactivity disorder
19 76965 13 38815028 39075356 Duplication or deletion LHFPL6 Attention deficit hyperactivity disorder
20 78033 13 48967801 49001118 Duplication or deletion PHF11 Attention deficit hyperactivity disorder
21 78043 13 49004082 49057720 Duplication or deletion RCBTB1 Attention deficit hyperactivity disorder
22 79472 13 72254230 72488592 Duplication or deletion PIBF1 Attention deficit hyperactivity disorder
23 91412 15 30110017 30248527 Deletion CHRNA7 Attention deficit hyperactivity disorder
24 99563 16 27600000 34400000 Deleted MAPK3 Attention deficit hyperactivity disorder
25 99685 16 28100000 34600000 Deletion CORO1A Attention deficit hyperactivity disorder
26 101713 16 45500000 51200000 Duplicated ZNF423 Attention deficit hyperactivity disorder
27 103489 16 6072599 6783832 Duplication RBFOX1 Attention deficit hyperactivity disorder
28 106366 16 87694595 87778383 Deletion CDH15 Attention deficit hyperactivity disorder
29 109330 17 25613604 26191779 Duplication BLMH Attention deficit hyperactivity disorder
30 117083 17 71112486 71120734 Deletion Attention deficit hyperactivity disorder
31 122044 18 52000000 54400000 Duplicated NEDD4L Attention deficit hyperactivity disorder
32 123018 18 65358832 65367619 Deletion DOK6 Attention deficit hyperactivity disorder
33 125924 19 15992679 15997923 Deletion Attention deficit hyperactivity disorder
34 127980 19 38427720 38444834 Deletion SLC7A10 Attention deficit hyperactivity disorder
35 127981 19 38427720 38444834 Deletion Attention deficit hyperactivity disorder
36 132645 19 59423491 59428132 Duplication LILRB3 Attention deficit hyperactivity disorder
37 132646 19 59423491 59428132 Duplication LILRB3 Attention deficit hyperactivity disorder
38 136696 2 132200000 134800000 Deleted NCKAP5 Attention deficit hyperactivity disorder
39 139372 2 1792886 2335045 Duplication or deletion MYT1L Attention deficit hyperactivity disorder
40 146272 2 47600000 52700000 Deleted NRXN1 Attention deficit hyperactivity disorder
41 146517 2 50145643 51259674 Duplication or deletion NRXN1 Attention deficit hyperactivity disorder
42 146826 2 55088956 55239201 Duplication RTN4 Attention deficit hyperactivity disorder
43 148301 2 75400000 83700000 Deleted CTNNA2 Attention deficit hyperactivity disorder
44 148598 2 81419297 81446082 Duplication CTNNA2 Attention deficit hyperactivity disorder
45 148599 2 81419297 81446082 Duplication Attention deficit hyperactivity disorder
46 154924 20 5000000 9000000 Deleted BMP2 Attention deficit hyperactivity disorder
47 164095 22 34870070 34916870 Het APOL3 Attention deficit hyperactivity disorder
48 164096 22 34870070 34916870 Het APOL4 Attention deficit hyperactivity disorder
49 164674 22 38384374 38403731 Deletion CACNA1I Attention deficit hyperactivity disorder
50 166998 3 111722434 117006477 Deletion Attention deficit hyperactivity disorder

Expression for Attention Deficit-Hyperactivity Disorder

Search GEO for disease gene expression data for Attention Deficit-Hyperactivity Disorder.

Pathways for Attention Deficit-Hyperactivity Disorder

Pathways related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
10.35 SLC6A3 COMT
Show member pathways

GO Terms for Attention Deficit-Hyperactivity Disorder

Biological processes related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine metabolic process GO:0042417 9.67 DRD4 COMT
2 synaptic transmission, dopaminergic GO:0001963 9.62 DRD5 DRD4
3 regulation of dopamine metabolic process GO:0042053 9.46 SLC6A3 DRD4
4 regulation of biological quality GO:0065008 9.26 DRD5 DRD4
5 dopamine catabolic process GO:0042420 9.26 SLC6A3 COMT
6 dopamine receptor signaling pathway GO:0007212 9.1 GNB5 DRD5 DRD4

Molecular functions related to Attention Deficit-Hyperactivity Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopamine neurotransmitter receptor activity GO:0004952 9.26 DRD5 DRD4
2 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4

Sources for Attention Deficit-Hyperactivity Disorder

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....